Sunesis Pharmaceuticals Inc (SNSS) Files Form 4 Insider Buying : Geoffrey M. Parker Buys 9,500 Shares

Sunesis Pharmaceuticals Inc (SNSS): Geoffrey M. Parker , director of Sunesis Pharmaceuticals Inc purchased 9,500 shares on May 26, 2016. The Insider buying transaction was reported by the company on May 27, 2016 to the Securities and Exchange Commission. The shares were purchased at $0.47 per share for a total value of $4,454.55 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 26, 2016, Geoffrey M. Parker (director) purchased 52,505 shares at $0.47 per share price.On Dec 21, 2015, Dayton Misfeldt (director) purchased 1,750,000 shares at $0.84 per share price.Also, On Aug 26, 2015, Daniel N Jr Swisher (CEO) purchased 25,000 shares at $1.01 per share price.On Jul 29, 2015, Eric Bjerkholt (EVP, CFO & Corp. Secretary) sold 6,358 shares at $3.46 per share price.

Sunesis Pharmaceuticals: On Wednesday, May 25, 2016 heightened volatility was witnessed in Sunesis Pharmaceuticals which led to swings in the share price. The shares opened for trading at $0.479 and hit $0.495 on the upside , eventually ending the session at $0.4932, with a gain of 2.96% or 0.0142 points. The heightened volatility saw the trading volume jump to 1,66,708 shares. The 52-week high of the share price is $3.72 and the company has a market cap of $43 M . The 52-week low of the share price is at $0.438.

Sunesis Pharmaceuticals Money Flow Index Chart

Sunesis Pharmaceuticals Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company’s program is QINPREZOTM (vosaroxin) which is its product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD) which is a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin is an AQD which is used for the treatment of cancer. MLN2480 is an oral investigative drug selective for pan-Raf kinase inhibition in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). PDK1 is a kinase and mediator of PI3K/AKT signaling which is a pathway involved in cell growth differentiation survival and migration.

Leave a Reply

Sunesis Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Sunesis Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.